Best Practice Series: Type 2 Diabetes

Metformin still best first-line oral hypoglycemic drug for type 2 diabetes

Reuters Health • The Doctor's Channel Daily Newscast

Metformin still best first-line oral hypoglycemic drug for type 2 diabetes
NEW YORK (Reuters Health) – An updated review of medications available for treating type 2 diabetes concludes that metformin continues to have the best benefit-to-harm profile, according to a report in the Annals of Internal Medicine online March 14. “In the U.S., eleven unique classes of medication are...

Both amitriptyline and duloxetine ease diabetic neuropathy

Reuters Health • The Doctor's Channel Daily Newscast

Both amitriptyline and duloxetine ease diabetic neuropathy
NEW YORK (Reuters Health) – Pain associated with diabetic neuropathy is improved to a similar degree with daily amitriptyline or duloxetine, according to the results of a cross-over trial conducted in India. While both the tricyclic antidepressant, amitriptyline, and the selective serotonin norepinephrine...

Editor of Journal of Diabetes Agrees with FDA Decision on Avandia

A Critical Analysis of the Data behind the Avandia Decision

Editor of Journal of Diabetes Agrees with FDA Decision on Avandia
Zachary T. Bloomgarden, MD, Editor of the Journal of Diabetes and a Clinical Professor at the Mount Sinai School of Medicine, provides a critical analysis of the recent FDA decision of keeping Avandia on the market. Disclosures:Speaker’s Bureau: Merck, NovoNordisk, GSKAdvisory Panel: Merck, BMS,...